FMP

FMP

Enter

JNJ - Johnson & Johns...

photo-url-https://images.financialmodelingprep.com/symbol/JNJ.png

Johnson & Johnson

JNJ

NYSE

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

156.31 USD

0.4 (0.256%)

Historical Prices

From:

To:

155.05155.5156156.5157157.5157.7309:30 AM09:50 AM10:10 AM10:30 AM10:50 AM11:10 AM11:30 AM11:50 AM12:10 PM12:30 PM12:50 PM01:10 PM01:30 PM01:50 PM02:10 PM02:30 PM02:50 PM03:10 PM03:30 PM03:50 PM

About

ceo

Mr. Joaquin Duato

sector

Healthcare

industry

Drug Manufacturers - General

exchange

NYSE

Description

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive banda...

CIK

0000200406

ISIN

US4781601046

CUSIP

478160104

Address

One Johnson & Johnson Plaza

Phone

732 524 0400

Country

US

Employee

138,100

IPO Date

Jan 2, 1943

Financial Statement

05B10B15B20B25B2024 Q12024 Q22024 Q32024 Q42025 Q1RevenueNet Income

Earnings

00.511.522.532023 Q32023 Q42023 Q42024 Q12024 Q22024 Q32024 Q42025 Q1EPS Consensus

JNJ Financial Summary

CIK

0000200406

Exchange

NYSE

Industry

Drug Manufacturers -...

Sector

Healthcare

CUSIP

478160104

ISIN

US4781601046

Country

US

Price

156.31

Beta

0.48

Volume Avg.

9.73M

Market Cap

376.68B

Shares

-

52-Week

140.68-169.99

DCF

221.51

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

17.37

P/B

-

Website

https://www.jnj.com

Upgrades and Downgrades

Rating Distribution

Buy2

Hold1

Sell0

TheFly

15 days ago
Apr 16, 2025

Outperform

Outperform

TheFly

15 days ago
Apr 16, 2025

Market Perform

Market Perform

Latest JNJ News

Gordon Thompson

Apr 15, 2025

Johnson & Johnson's Impressive Financial Performance

Johnson & Johnson (NYSE:JNJ) is a multinational corporation known for its wide range of healthcare products, including pharmaceuticals, medical devices, and consumer health goods. The company competes with other major players in the healthcare industry, such as Pfizer and Merck. On April 15, 2025, JNJ reported impressive financial results, showcasing its strong market position. The company reported earnings per share (EPS) of $2.77, surpassing the estimated $2.58. This result also exceeded the ...

Parth Sanghvi

Apr 15, 2025

Johnson & Johnson Q1 Earnings Beat Estimates, Boosts Sales F...

Johnson & Johnson (NYSE: JNJ) delivered a solid Q1 performance, surpassing Wall Street expectations for both revenue and profit, as its pharmaceutical arm continues to shine — particularly in oncology. Despite some drag from biosimilar competition and U.S. tariffs, the company lifted its full-year revenue outlook, banking on its growing drug portfolio. Q1 2025 Highlights Revenue: $21.89 billion (+2.4% YoY) Adjusted EPS: $2.77 (vs. $2.59 est.) Innovative Medicines revenue: $13.87 bill...

Alex Lavoie

Apr 11, 2025

Johnson & Johnson (NYSE:JNJ) Quarterly Earnings Preview

Johnson & Johnson (NYSE:JNJ) is a global leader in the healthcare sector, known for its diverse range of products in pharmaceuticals, medical devices, and consumer health. As the company prepares to release its quarterly earnings on April 15, 2025, Wall Street analysts predict an earnings per share (EPS) of $2.59 and revenue of approximately $21.6 billion. Analysts are closely examining Johnson & Johnson's financial metrics to gain a deeper understanding of its performance. The company's price-...

Davit Kirakosyan

Apr 4, 2025

Johnson & Johnson Faces Pressure to Deliver After Talc Setba...

UBS reaffirmed its Buy rating on Johnson & Johnson (NYSE:JNJ) and maintained a $180 price target, but highlighted short-term volatility risks following the latest legal setback in the company’s ongoing talc litigation saga. A recent court decision marked the third rejection of J&J’s attempt to use bankruptcy proceedings as a pathway to resolve current and future talc-related lawsuits — despite reportedly having over 75% support from claimants. UBS notes that this has significantly dented investo...

Davit Kirakosyan

Apr 1, 2025

TD Cowen Maintains Buy on Johnson & Johnson Despite Talc Set...

TD Cowen reaffirmed its Buy rating and $185 price target on Johnson & Johnson (NYSE:JNJ) following news that a federal judge rejected the company's latest bankruptcy-based proposal to settle its talc-related lawsuits, which pushed the stock price down more than 5% intra-day today. According to the report, the court took issue with the voting process tied to the proposed trust structure, which was designed to handle claims outside of traditional litigation channels. While Johnson & Johnson has no...

Andrew Wynn

Jan 24, 2025

Johnson & Johnson (NYSE:JNJ) Faces Investigation 

Johnson & Johnson (NYSE:JNJ) is a well-known multinational corporation involved in the development and sale of healthcare products. The company operates in three main segments: Consumer Health, Pharmaceutical, and Medical Devices. It faces competition from other major healthcare companies like Pfizer and Merck. Recently, J&J has come under scrutiny due to an investigation by Pomerantz LLP regarding potential securities fraud. The investigation by Pomerantz LLP follows J&J's decision to pause th...

Stuart Mooney

Jan 23, 2025

Johnson & Johnson (NYSE:JNJ) Surpasses Earnings Expectat...

Johnson & Johnson (NYSE:JNJ) is a global healthcare company known for its pharmaceuticals, medical devices, and consumer health products. The company competes with other major players like Pfizer and Merck. On January 22, 2025, JNJ reported earnings per share (EPS) of $2.04, surpassing the estimated $1.99. The company also reported revenue of $22.52 billion, exceeding the estimated $22.45 billion. Despite these positive earnings, JNJ's stock experienced a decline. This dip followed the release ...

Davit Kirakosyan

Jan 22, 2025

Johnson & Johnson Exceeds Q4 Expectations with Strong Oncolo...

Johnson & Johnson (NYSE:JNJ) delivered fourth-quarter results that surpassed Wall Street expectations, driven by robust demand for its cancer treatments and strategic acquisitions. The pharmaceutical giant also provided an upbeat forecast for 2025, projecting full-year sales of $90.9 billion to $91.7 billion and adjusted earnings per share of $10.75 to $10.95, both above analyst estimates. Revenue for the quarter climbed 5.3% year-over-year to $22.52 billion, bolstered by a remarkable 19% increa...

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep